Makkah, Saudi Arabia. – AbbVie, a research-based global biopharmaceutical company, and Arab Company for Pharmaceutical Products (ARABIO) have today announced that it has reached the milestone of manufacturing one million packs of medication since the beginning of their partnership six years ago.
The agreement between AbbVie and Arab Company for Pharmaceutical Products (ARABIO) was formed in 2014 to develop biologic manufacturing capabilities in the Kingdom.
Commenting on this significant milestone for AbbVie, Ashraf Dawoud, general manager for AbbVie Saudi Arabia said: “When we embarked on this journey with ARABIO six years ago, our core priority was to ensure increased medication access for patients across Saudi Arabia, as well as to elevate Saudi Arabia’s biologic manufacturing capabilities. I am extremely proud to announce that we have now locally produced our one millionth pack of different medications including biological medication. This is a tremendous achievement for us at AbbVie. We are extremely proud to contribute to Saudi Arabia’s healthcare vision and pledge to continually make a remarkable impact on patient’s lives through increasing access to our key life-changing therapies.”
Dr. Abdulrahman Almutairi, Arabio CEO, added: “Since 2014, we have been proud to work closely with AbbVie to help strengthen, localize and develop Saudi Arabia’s manufacturing capabilities by using up to date technology. This collaboration has ensured the uninterrupted supply of key medications to patients across the Kingdom. We look forward to continuing our partnership to further enhance and localize the field of biotechnology and manufacturing.”
Recently, to ensure increased access to key therapies, AbbVie has also implemented a program to deliver medicine to homes to cover all parts of the Kingdom. AbbVie has collaborated with different hospitals in Saudi Arabia to support with Home Delivery boxes that could help serve around 1,800 patients monthly. This would allow patients in remote areas to receive their medications on time without any delay or far travels, especially in an era of COVID-19.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
